Navigation Links
Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
Date:11/5/2010

s from the September 2010 financing, was approximately $37.6 million.
  • For 2010, management anticipates total operating expenses will be $3 to $5 million less than those reported for 2009, which were approximately $72 million. Excluding the proceeds from the financing, the company continues to expect a net cash burn of $40 to $45 million for the year 2010.

  • Upcoming Corporate PresentationHalozyme representatives are scheduled to present at the following investor conference:

  • Lazard Capital Markets 7th Annual Healthcare Conference, November 17, 2010, 8:30 a.m. EST, New York City

  • To listen to the live webcast or a replay of the presentation, please visit the Investor Relations section of the company's Web site at www.halozyme.com. The replay will be available for 90 days after the event.

    Conference CallHalozyme management will host a conference call and webcast on November 5, 2010 to discuss these topics beginning at 8:00 a.m. PDT (11:00 a.m. EDT). To participate via telephone, please call 877.407.8037 for domestic callers or 201.689.8037 for international callers. A telephone replay will be available beginning shortly after the end of the call by dialing 877.660.6853 from the U.S. or 201.612.7415 for international callers and using account # 367 and replay ID # 359750. The conference call will be broadcast live over the Internet at www.halozyme.com and the replay will be available on the company's Web site for seven days.

    About Halozyme TherapeuticsHalozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the endocrinology, oncology, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extra
    '/>"/>

    SOURCE Halozyme Therapeutics, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7

    Related biology technology :

    1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
    2. Halozyme Therapeutics Strengthens Management Team, Appoints Additional Experienced Executives
    3. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    4. Halozyme Therapeutics Appoints Head of Endocrinology Clinical Development
    5. Halozyme Therapeutics to Host Research Day for Investors and Analysts
    6. Halozyme Therapeutics to Present at Upcoming Investor Conferences
    7. Halozyme Therapeutics Announces Conference Call on November 6 to Review Third Quarter Results
    8. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
    9. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
    10. Halozyme Receives $5.5 Million Payment From Baxter
    11. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... Aug. 21, 2014  Decision Resources Group finds ... and Mexico ... several newly approved agents, the anticipated label extension ... the launch of emerging biologics will substantially increase ... the emerging IL-5 inhibitors will introduce a new dynamic ...
    (Date:8/21/2014)... 2014 Pursuit Solutions ( http://www.pursuit-solutions.com ... and services for Life Sciences sales and marketing ... of New Commercial Sales Models” by Peter Robinson, ... The article examines some innovative models used to ... tested in the pharmaceutical market. Robinson grades the ...
    (Date:8/20/2014)... 20, 2014 Clintrax Global, Inc., a ... Raleigh, NC , recently announced ... Vice President of Administration. As ... corporate processes, including their alignment with company objectives ... worked as an HR executive, specializing in needs ...
    (Date:8/20/2014)... Livermore, California (PRWEB) August 20, 2014 ... to develop and apply the most complete climate ... challenging and demanding climate change issues. , Eight ... combining forces with the National Center for Atmospheric ... in the new effort. Other participating national laboratories ...
    Breaking Biology Technology:Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 2Asthma Agents Currently Face a Suboptimal Coverage Environment in Brazil and Mexico, and as the Treatment Armamentarium Expands, Competitiveness Will Further Intensify 3Pursuit's Peter Robinson Publishes "Grading Pharma's Use of New Commercial Sales Models" 2Clintrax Global, Inc. Announces Addition to Executive Team 2New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3
    ... April 23 ImaRx Therapeutics,Inc. (Nasdaq: IMRX ... an agreement,with Abbott Laboratories pursuant to which it ... promissory note with Abbott issued in,connection with its ... to,the urokinase assets, including the remaining inventory of ...
    ... PHILADELPHIA, April 23 BioNanomatrix, Inc. today,announced that ... honored at the,14th Annual Ben Franklin Emerging Business ... Management Team category, competing with a,strong group of ... executive officer Dr. Michael Boyce-Jacino accepted the,award on ...
    ... Calif., April 23 SectorWatch.biz announces the,availability ... news and driving,markets today within the biotechnology ... on the aforementioned equities and the,opportunity for ... on the,subject and sector., Investors can ...
    Cached Biology Technology:ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 2ImaRx Therapeutics Satisfies Abbott Note Obligation Associated With the Acquisition of Urokinase 3BioNanomatrix Named 'Best Management Team' at the 2008 Ben Franklin Emerging Business Awards 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 2SectorWatch.biz Issues MarketStats on KBLB, DGX, LH, BRLI, and ABT 3
    (Date:8/20/2014)... POINT ROBERTS, Washington , August 20, 2014 ... Role in Addressing Security Concerns in the Payment Industry? ... source covering leading sectors including biometrics, issues commentary from analysts ... Jason Peaslee , Managing Partner at Thrive Analytics, ... Pereira , CEO of NXT-ID, Inc. (OTCBB: NXTD) ( OTCQB:NXTD ...
    (Date:8/19/2014)... caesarean section rate, suggests a new commentary published today ... Obstetrics and Gynaecology (BJOG) . , China has one ... Of 16 million babies born in 2010, approximately half ... known, the current Chinese language literature on caesarean rates ... to 58%. However, before the 1980s, the caesarean rate ...
    (Date:8/19/2014)... used in supermarkets to encourage healthier spending habits? A ... that very question by tracking the purchasing records in ... to rate the nutritional value of foods for sale. ... David Just, PhD, and Brian Wansink PhD, author of ... over 150 Hannaford Supermarkets in the Northeastern United States ...
    Breaking Biology News(10 mins):Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 2Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 3Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 4Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 5Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 6Digital Wallets for a Digital World - the Players and the Concerns for Consumer Adoption 7Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3
    ... United Nations Intergovernmental Panel on Climate Change (IPCC) have warned ... achieve a stable climate on our planet by the end ... coming decades must be curbed before the emissions can be ... CO2 emissions that can be tolerated globally by the end ...
    ... genetically modified crops, according to new research funded by ... A group at the Open University, led by Professor ... what large-scale, commodity farmers not those mainly involved ... know how consumers, governments and the food industry regard ...
    ... University of Nottingham could have a major impact on the ... to stay in work. Back pain is one of ... In 2004-5 approximately 34,000 people in the East Midlands suffered ... caused or made worse by their current or past work. ...
    Cached Biology News:ETH Zurich competence center ESC introduces energy strategy 2ETH Zurich competence center ESC introduces energy strategy 3What farmers think about GM crops 2Helping back pain sufferers to stay in work 2
    ... kits are designed to rapidly and reliably ... patented APA Technology. APAgene provides hassle-free, ready-to ... All necessary ingredients are provided in each ... used for gap filling, localized cloning of ...
    N,N'-Methylene-bis-acrylamide, Ultra Pure...
    ... product is designed to deparaffinize and perform ... fixed paraffin-embedded tissue sections mounted on glass ... the paraffin at the high temperature used ... emulsification of the paraffin by detergent. Formaldehyde ...
    ... product is designed to deparaffinize and perform ... fixed paraffin-embedded tissue sections mounted on glass ... the paraffin at the high temperature used ... emulsification of the paraffin by detergent. Formaldehyde ...
    Biology Products: